Profil
Bradlee Heckmann is the founder of Asha Therapeutics LLC.
He held the title of Chief Scientific Officer at the company.
Postes actifs de Bradlee Heckmann
| Sociétés | Poste | Début |
|---|---|---|
Asha Therapeutics LLC
 Asha Therapeutics LLC Pharmaceuticals: OtherHealth Technology Asha Therapeutics LLC is an American life sciences company that specializes in precision drug design using its Prism™ technology to create curative therapeutics for diseases with high unmet medical needs in neurology, oncology, and infectious disease. Asha Therapeutics is located in the US. The company's lead therapeutic programs, Asha-624 and Asha-091, are expected to enter clinical trials by mid-2024 and are disease-modifying therapeutics for indications in amyotrophic lateral sclerosis, Parkinson's disease, and ME/CFS and long COVID, respectively. | Fondateur | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Asha Therapeutics LLC
Asha Therapeutics LLC Pharmaceuticals: OtherHealth Technology Asha Therapeutics LLC is an American life sciences company that specializes in precision drug design using its Prism™ technology to create curative therapeutics for diseases with high unmet medical needs in neurology, oncology, and infectious disease. Asha Therapeutics is located in the US. The company's lead therapeutic programs, Asha-624 and Asha-091, are expected to enter clinical trials by mid-2024 and are disease-modifying therapeutics for indications in amyotrophic lateral sclerosis, Parkinson's disease, and ME/CFS and long COVID, respectively. | Health Technology |
